GLENFIELD BIOMED LTD

Company Registration Number:
13914641 (England and Wales)

Unaudited abridged accounts for the year ended 28 February 2023

Period of accounts

Start date: 14 February 2022

End date: 28 February 2023

GLENFIELD BIOMED LTD

Contents of the Financial Statements

for the Period Ended 28 February 2023

Company Information - 3
Profit and Loss Account - 4
Balance sheet - 5
Additional notes - 7
Balance sheet notes - 10

GLENFIELD BIOMED LTD

Company Information

for the Period Ended 28 February 2023




Registered office: Flat 12 County Mews
Sandes Avenue
Kendal
Cumbria
England
LA9 4LL
Company Registration Number: 13914641 (England and Wales)

GLENFIELD BIOMED LTD

Profit and Loss Account

for the Period Ended 28 February 2023


Notes

2023
£
Gross Profit or (Loss) 17,479
Income from coronavirus (COVID-19) business support grants 0
Distribution Costs ( 0 )
Administrative Expenses ( 16,100 )
Operating Profit or (Loss) 1,379
Interest Receivable and Similar Income 0
Interest Payable and Similar Charges ( 0 )
Profit or (Loss) Before Tax 1,379
Tax on Profit ( 262 )
Profit or (Loss) for Period 1,117

The notes form part of these financial statements

GLENFIELD BIOMED LTD

Balance sheet

As at 28 February 2023


Notes

2023
£
Fixed assets
Intangible assets: 4 0
Tangible assets: 5 5,300
Total fixed assets: 5,300
Current assets
Stocks: 236
Debtors: 0
Cash at bank and in hand: 6,700
Total current assets: 6,936
Prepayments and accrued income: 0
Creditors: amounts falling due within one year: ( 0 )
Net current assets (liabilities): 6,936
Total assets less current liabilities: 12,236
Creditors: amounts falling due after more than one year: ( 0 )
Provision for liabilities: ( 0 )
Accruals and deferred income: ( 0 )
Total net assets (liabilities): 12,236

The notes form part of these financial statements

GLENFIELD BIOMED LTD

Balance sheet continued

As at 28 February 2023


Notes

2023
£
Capital and reserves
Called up share capital: 10,836
Profit and loss account: 1,400
Shareholders funds: 12,236

For the year ending 28 February 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 3 November 2023
And Signed On Behalf Of The Board By:

Name: BLESSING TACHIONA
Status: Director

The notes form part of these financial statements

GLENFIELD BIOMED LTD

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 1. Accounting policies

    Basis of measurement and preparation

    historical cost,value of business,realisable value and value in use

GLENFIELD BIOMED LTD

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 2. Employees


    2023
    Average number of employees during the period 0

    the company has the working directors only ,so it was a small business to run there was no need to engage employees

GLENFIELD BIOMED LTD

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 3. Off balance sheet disclosure

    No

GLENFIELD BIOMED LTD

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 4. Intangible assets

    Total
    Cost £
    Additions -
    Disposals -
    Revaluations -
    Transfers -
    At 28 February 2023 -
    Amortisation
    Charge for year -
    On disposals -
    Other adjustments -
    Amortisation at 28 February 2023 -
    Net book value
    Net book value at 28 February 2023 -

    no intangible asssets

GLENFIELD BIOMED LTD

Notes to the Financial Statements

for the Period Ended 28 February 2023

5. Tangible Assets

Total
Cost £
Additions 5,300
Disposals -
Revaluations -
Transfers -
At 28 February 2023 5,300
Depreciation
Charge for year -
On disposals -
Other adjustments -
At 28 February 2023 -
Net book value
At 28 February 2023 5,300

we didnt charge depreciation on our assets.The assets include office furnitures laptops printer and ipads